We are live on ! Find out more

KARD

Kardigan Inc

KARD

Market cap $1.42B

15.18 USD

-0.34

2.19%

At close Updated Nov 9, 4:00 PM EST

1 day

-2.19%

5 days

6.68%

1 month

3.48%

3 months

-27.99%

6 months

-31%

Year to date

-31%

1 year

-31%

5 years

-31%

10 years

-31%

About: Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 85.7%

Negative 0%

Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript

Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript

Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript

Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results

Kardigan NASDAQ: KARD said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study's primary endpoint at 48 weeks, rather than 24 weeks. Top-line results are expected in the second half of 2027.

Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS).

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee.

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key clinical readouts before further funding is needed. Upcoming 2027 data from all three lead programs will be pivotal in validating KARD's hypotheses and informing future capital allocation.

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan to Present at Two September Investor Conferences

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference.

Kardigan to Present at Two September Investor Conferences

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

See News Rankings

Price charts implemented using Lightweight Charts™